Skip to content
NoBlaBlaFinance
FilingsCompaniesSectorsCalendar
Log inFrançais
Inside informationEnglish

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Sanofi

The file is served by the AMF. We do not host a copy.

Document type

Issuer
Sanofi
Filed
25/11/2025, 07:00
Document type
Inside information
AMF sub-type
Informations privilégiées
Language
English
AMF reference
110718_20251125